about
Nutritional therapy, phosphate control and renal protectionEndocrine alterations and cardiovascular risk in CKD: is there a link?Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortalityMechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal diseaseThe relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease.Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilationGonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options.Comparative associations of muscle mass and muscle strength with mortality in dialysis patients.Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?Dietary fiber, kidney function, inflammation, and mortality risk.Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction.Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survivalKidney function, β-cell function and glucose tolerance in older men.Nonesterified fatty acids and cardiovascular mortality in elderly men with CKDMortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry.Parental history of premature cardiovascular disease, estimated GFR, and rate of estimated GFR decline: results from the Aerobics Center Longitudinal Study.Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal diseaseBaseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patientsProlactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.Critical appraisal of biomarkers of dietary intake and nutritional status in patients undergoing dialysis.Does nutrition have a role in peripheral vascular disease?Adipokine signaling in the peritoneal dialysis patient.ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences.Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.Understanding the role of genetic polymorphisms in chronic kidney disease.Low serum testosterone increases mortality risk among male dialysis patients.Cytokine dysregulation in chronic kidney disease: how can we treat it?Influence of body mass index on the association of weight changes with mortality in hemodialysis patientsIncreased risk of fatal infections in women starting peritoneal dialysisMediterranean diet, kidney function, and mortality in men with CKD.CCR5 deletion protects against inflammation-associated mortality in dialysis patients.Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach.Identification of patients with eating disorders: clinical and biochemical signs of appetite loss in dialysis patients.Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin.Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad.
P50
Q27011477-FAC61CA2-E6CF-4F9F-986C-624E06B34CE6Q27022937-373EEFCC-215C-4F2E-8AB9-345831B5D56EQ28390958-BEF7C45A-2D8F-46A4-BBAE-ECECF23D3D68Q28730306-2B28EB3C-ECD3-4608-BCC3-CAE28AF19914Q30361177-0ED11666-D30E-4AA6-ACD1-E7F24DEF045FQ33345061-1AFFC752-A60D-430D-8D2C-6F79DAA6CA3EQ33944773-30F97E71-AB6A-4C13-BFBB-37A2B5D68832Q34199708-F3638EC8-BBA3-4555-B768-98D7B6AAA011Q34292906-DA0188A2-7921-4A0B-9B94-72D1E3D6285DQ34405392-EEB76B1A-7F9C-4020-887F-C61D8B8DB497Q34629709-680089A7-EE1B-44F4-8331-D6377E45F424Q34713240-1E2ED556-2DF3-4DF1-86F0-019A104BD2DCQ34751855-3E318A99-8D2B-46CB-8F84-F16459D25B27Q34926791-47E9AF41-8C25-4799-9E63-24E51312AA0DQ35055095-2463E8EA-6D62-4430-92C9-0AC6B1F240AEQ35278551-A0E593C2-1526-4432-9664-6C89A5D843F6Q35552358-2A6704EE-3BAC-4DB9-BE8E-6E7204990B24Q35554050-B63EAD40-9784-4DF0-9C1A-996C2C3DDF03Q35664554-20948AB9-1687-4004-8206-F08306C9B3F2Q35692463-8F89ADA4-188E-408B-B276-2568E7C418A5Q35758553-44566B25-1932-4A68-A588-F28D61F09C64Q36064124-31AE25CC-95D6-45D3-A9A5-1C4817726706Q36392251-850686C3-1653-4C9C-A929-EE069DE12E72Q36487247-C8EE5AB2-617D-440F-B0CE-29D8F881D9D3Q36677348-A70FC905-6998-4017-BD3E-702D8753D6A5Q36912429-3512360A-EACE-4D6D-A564-D5955F22BC76Q37042084-2701A08F-E8E3-45CD-A54A-730FB8FC05E4Q37119827-C570B55C-EA58-47F7-B5AA-99CF33EFBDAAQ37123233-3D81B7B6-98E7-433D-A4D8-38967D65E6B3Q37141709-84FC2652-0E07-48EF-A6DE-105BB2BF5317Q37212390-C72DFA60-25DE-45FB-907D-06E565091026Q37232273-BC45E7BA-FC13-4A0E-900D-B8C0E00129FAQ37246956-358E60B2-58EB-48C0-B1A1-4A0210C75F91Q37259261-84EDE57A-6731-494E-A3A1-14A60FCD17AFQ37307738-A1AFE7A3-93D4-48D1-A886-AE1591FF93BEQ37361911-78C85620-AD6C-4B98-86BE-C28C6B91DF7FQ37415728-5A7AC132-4AAC-4538-8D22-9EE1BFFD6CF9Q37456616-50552928-8547-4814-A83E-DF8AE62057D2Q37565721-5215B2A1-2BB1-4069-A645-DEC0C1671DAEQ37587296-9359B2EB-8DBD-4BA2-86F0-F4347B6B31E7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juan J Carrero
@ast
Juan J Carrero
@en
Juan J Carrero
@es
Juan J Carrero
@nl
Juan J Carrero
@sl
type
label
Juan J Carrero
@ast
Juan J Carrero
@en
Juan J Carrero
@es
Juan J Carrero
@nl
Juan J Carrero
@sl
prefLabel
Juan J Carrero
@ast
Juan J Carrero
@en
Juan J Carrero
@es
Juan J Carrero
@nl
Juan J Carrero
@sl
P106
P21
P31
P496
0000-0003-4763-2024